WO2002011718A1 - Inhibiteurs de production d'ige - Google Patents
Inhibiteurs de production d'ige Download PDFInfo
- Publication number
- WO2002011718A1 WO2002011718A1 PCT/JP2001/006704 JP0106704W WO0211718A1 WO 2002011718 A1 WO2002011718 A1 WO 2002011718A1 JP 0106704 W JP0106704 W JP 0106704W WO 0211718 A1 WO0211718 A1 WO 0211718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gla
- ige
- acid
- ige production
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an IgE production inhibitor, and more particularly to an agent which can be used for treating diseases caused by IgE production, particularly for treating skin conditions.
- BACKGROUND ART Arlinolenic acid is one of the representative unsaturated fatty acids and is a straight-chain triene fatty acid having 18 carbon atoms having a cis double bond at positions 6, 9, and 12. Arlinolenic acid is contained in evening primrose seed oil at 8 to 10% and is used in health foods and other products.
- Arlinolenic acid is used as various pharmaceutical ingredients.
- a therapeutic drug for allergic rhinitis or allergic asthma containing linolenic acid as an active ingredient Japanese Patent Application Laid-Open No. 61-8762
- dialysis patients containing ⁇ -, J-norenic acid or dihomo-monolinolenic acid etc.
- a composition for treating pruritus cutaneous and hyperparathyroidism Japanese Patent Application Laid-Open No.
- Hei 7-233062 containing a-linolenic acid or dihomo-a-linolenic acid, atopic eczema, rheumatoid arthritis, coronary artery
- An external preparation for hair treatment after depilatory treatment, which contains fortified fruit juice Japanese Patent Application Laid-Open No. 8-205832
- arlinolenic acid or dihomo-arinolenic acid which is effective for the treatment and prevention of diseases, asthma, diabetes, prostate disease, etc.
- Japanese Patent Application Laid-Open No. 10-218731 Japanese Patent Application Laid-Open No. 10-218731
- An object of the present invention is to provide a novel IgE production inhibitor that can be used for treating diseases caused by IgE production, particularly for treating skin conditions and the like.
- the present inventors have conducted intensive research to solve the above-mentioned problems, and as a result, have found that The inventors have found that an acid has an IgE production inhibitory action, and have completed the present invention.
- the present invention is an IgE production inhibitor containing, as an active ingredient, one or more selected from arlinolenic acid, dihomo-alinolenic acid and derivatives thereof.
- the present invention also provides a gE production inhibitor, which is administered at an amount of 0.3 mg / kg / day or more as the amount of the active ingredient.
- a gE production inhibitor which is administered at an amount of 0.3 mg / kg / day or more as the amount of the active ingredient.
- the IgE production inhibitor of the present invention comprises one or more selected from arlinolenic acid, dihomo-monolinolenic acid and derivatives thereof (hereinafter, also referred to as “arinolenic acid etc.”) as an active ingredient. contains.
- filamentous fungi such as the genus Mortierella (Morti ⁇ re 11a), the genus Mucor, and the genus Rhizopus are used.
- filamentous fungi such as the genus Mortierella (Morti ⁇ re 11a), the genus Mucor, and the genus Rhizopus are used.
- it is obtained from oils and fats contained in plants such as evening primrose and borage, and also in algae such as spirulina. Extracts from these may be used as they are or purified ones.
- a filamentous fungus, spirulina, or the like may be used as it is without extraction.
- arino'lenic acid can be obtained by chemical synthesis, and commercially available ones may be used.
- extracts or crude products of microorganisms or plants containing a-linolenic acid or a derivative thereof can be used as long as they are pharmaceutically acceptable.
- Derivatives such as arlinolenic acid include esters obtained by reacting these with various alcohols, for example, ethyl esters, glycerol esters, phospholipids, etc., or inorganic and organic bases in an equimolar ratio. And the like, for example, sodium salt, potassium salt and the like.
- Arlinolenic acid, etc. is an essential fatty acid and is used for food, and it is considered that there is no particular problem in safety.
- the IgE production inhibitor of the present invention may contain, in addition to the active ingredient arlinolenic acid and the like, components used in ordinary pharmaceuticals or health foods.
- the dosage form of the IgE production inhibitor of the present invention is not particularly limited.
- One or more mixtures selected from homo- 7 -linolenic acid and derivatives thereof, extracts obtained from the above-mentioned oils and fats of filamentous fungi, plants, etc., or cells as such are generally formulated into One or more harmless or acceptable vehicles, carriers, excipients, integrators, preservatives, stabilizers, flavoring agents, etc., mixed with tablets, granules, capsules, water Oral preparations such as preparations; suppositories; vaginal preparations; external preparations such as ointments, creams and lotions; injections such as sterile solutions and suspensions.
- These can be manufactured using a conventionally known technique.
- the above-mentioned monolinolenic acid and the like, a binder such as corn starch and gelatin, an excipient such as microcrystalline cellulose, a leavening agent such as potato starch and sodium alginate, and a sweetener such as lactose and sucrose are distributed.
- Capsules are prepared by filling a mixture of arlinolenic acid and other fats and oils into a soft gelatin capsule, a hard gelatin capsule, or the like, according to a conventional method.
- a cyclodextrin clathrate of cyclodextrin and arlinolenic acid or the like can be obtained by a conventional method.
- vaseline, paraffin, oils and fats, lanolin and the like are used as bases.
- arlinolenic acid and the like include ⁇ 3-based unsaturated fatty acids such as hy-linolenic acid, eicosapentaenoic acid and docosahexane acid, acid, ⁇ 5-based unsaturated fatty acids such as myristoleic acid, and palmitoleic acid.
- An ⁇ 7 unsaturated fatty acid such as toleic acid, an ⁇ 9 unsaturated fatty acid such as oleic acid and erucic acid, and a saturated fatty acid such as lauric acid and myristic acid may be added at an arbitrary ratio.
- an antioxidant such as vitamin ⁇ , ascorbyl palmitate, or ascorbyl stearate may be added to prevent oxidation of a-linolenic acid or other fatty acids.
- the compounding amount of arlinolenic acid or the like is preferably 0.000 000-1 to 100% by weight of the total amount of the IgE production inhibitor, and 0.000 to 0.01 to 10% by weight. More preferably, it is 0% by weight.
- the present invention Since the IgE production inhibitor of the present invention can effectively suppress the production of IgE that causes immediate allergy, the prevention of symptoms, i.e., It can be used for so-called preventive treatment.
- diseases caused by IgE production include skin diseases caused by IgE production, atopic dermatitis, asthma, allergic rhinitis, allergic enteritis, hay fever, allergic conjunctivitis, and the like.
- the IgE production inhibitor of the present invention can be administered to a healthy person or a person having a constitution susceptible to the above-mentioned diseases to prevent the above-mentioned diseases, but in particular, patients expected to develop the above-mentioned diseases. It is effective to use for prevention of onset. In addition, if IgE production is not increased, it is expected to be administered to early stage patients with the above-mentioned diseases to reduce the symptoms.
- the dose is not particularly limited as long as it has an inhibitory effect on IgE production as the amount of monolinolenic acid or the like. However, if the dose is too large, loose stool tends to occur.
- the dose may be appropriately determined depending on the patient's age, weight, medical history, disease type, symptoms, and the like.
- the daily dose of arlinolenic acid or the like is preferably 0.3 to 1,000 mg / kg (body weight of the subject), more preferably 1 to 50 mg / kg.
- the expected effect can be expected by administering 0 mg / kg.
- FIG. 1 is a graph showing the time course of the disease score of NC / Nga mice.
- FIG. 2 is a graph showing the change over time in the total IgE amount in plasma of NC / Nga mice.
- FIG. 3 is a graph showing the time course of the disease score of NC / Nga mice.
- FIG. 4 is a graph showing the time course of the total IgE amount in the plasma of NC / Nga mice.
- FIG. 5 is a diagram showing the amount of IgE in the culture supernatant at each concentration of GLA added.
- FIG. 6 is a graph showing the cell proliferation ability (405 nm absorbance) at each concentration of GLA. Best shape bear for carrying out the invention First, the model animals used in the examples will be described.
- NC / Nga mice were used as model animals.
- the NC / Nga mouse is an inbred mouse that was established in 1957, originating from a toy mouse, Nishiki Rat. It has been known for some time that it is susceptible to anaphylactic shock to X-rays and ovalbumin.
- AD Matsuda et al. Reported that mice were atopic dermatitis in humans (hereinafter referred to as “AD”). ) Has been shown to exhibit a phenotype very similar to that of Int. I maraud unol., 9, 461-466 (1997).
- SPF specific pathogen-free
- GLA ethyl ester (purity: 95.98%, manufactured by Idemitsu Materials Co., Ltd.) was administered to these mice at a dose of 50 mg / individual once a day from the age of 5 weeks by gastric sonde method. Groups. Also, as a control, PBS (phosphate buffered saline) was similarly administered to 50 5 / individual in place of GLA ethyl ester, to prepare a control group consisting of 6 animals per group. In each week between the time of administration disclosure (5 weeks of age) and 19 weeks of age, the pathological scores of the mice were scored according to the method of Matsuda et al. (Int. Immunol., 9, 461-466, 1997). The specific method is shown below.
- the following five items A to E were scored on a scale of 0 (none), 1 (slightly worse), 2 (mediumly worse), and 3 (significantly worse). The total score is 15 points.
- B erythema, bleeding: Bleeding from the face of the ear, marking the erythema behind the ear.
- D (Abrasions, erosions): Mark the abrasions around the face, behind the ears, and around the base of the arms.
- a rat anti-mouse IgE monoclonal antibody (manufactured by PharMingen) diluted to 2 ⁇ g / ml with a coating solution (0.1 M NaHCOs, 0.5 M NaCl, pH 8.5) was applied to a plate (NUNC-IMMUNOPLATE, NUNC Add 50 ⁇ 1 to each well of), and place at 4 ° C for 3 hours at 37 ° C or 3 times with PBS / Tween (PBS, 0.05% Teen-20, pH7.5). Washed.
- a coating solution 0.1 M NaHCOs, 0.5 M NaCl, pH 8.5
- mouse plasma was diluted with a dilution buffer (PBS, 2% scan).
- the sample was diluted 100-fold with milk (0.25% SDS) to prepare a sample for measurement.
- a mouse IgE standard manufactured by PharMingen was diluted with a dilution buffer to prepare a measurement standard.
- Biotinyl rat anti-mouse IgE antibody (manufactured by PharMingen) diluted to 2 g / ml with a dilution buffer was added to each of the wells at 50 ⁇ 1 each, and incubated at 37 ° C for about 3 hours. Washed 6 times with PBS / Tween.
- alkaline phosphatase-labeled streptavidin manufactured by BioSource
- diluted 1000-fold with a dilution buffer is added to the wells at 50 ⁇ 1 each, incubated at 37 ° C for 1 hour, and incubated with PBS / Tween. Washed 6 times.
- AttoPhos TM B0EHRINGER MANNHEIM
- CytoFluo M II PE Biosystems
- Figure 1 shows the results of the mouse disease score.
- FIG. 2 shows the results of the total IgE amount in mouse plasma.
- the total IgE level tended to increase over time, but the GLA-administered group had a lower total IgE level at each measurement than the control group. In particular, it became clear that the total IgE level was significantly low at 11 weeks of age.
- GLA has an effect of suppressing IgE production.
- a 50 mg GLA oral administration test revealed that GLA was effective in suppressing the pathological progression and high IgE production of NC / Nga mice. Therefore, the effect of oral administration of GLA to the same mice at different doses and administration forms was examined.
- GLA ethyl ester purity: 95.98%, manufactured by Idemitsu Materials Co., Ltd.
- GLA was administered to these mice at a rate of 0.1 mg / individual once every two days by gastric sonde method.
- the administration of GLA was performed by adding 0.1 g of olive oil containing almost no essential fatty acid to 0.1 mg of GLA ethyl ester and setting it to 50-1. In the control group, only olive oil was similarly administered.
- mice in these groups the pathological score was measured every week, and the total IgE in plasma was measured every two weeks, as in Example 1.
- FIG. 3 shows the results of the disease state scores of the mice.
- mice Although scores vary depending on the individual differences between mice, the score generally increases from 6 weeks of age. In the control group, the skin became dry from 8 weeks of age, and the number of squeezing increased, and bleeding around the eyes, ears and face, and erythema on the torso began to be seen. As a result, there was a sharp rise in the score, and although there were a few waves, the symptoms were always poor and did not improve. On the other hand, the GLA-administered group showed a lower mean value after 9 weeks of age than the control group, and in particular, showed a significantly lower value by 15-17 weeks of age.
- FIG. 4 shows the result of the total IgE amount in mouse plasma.
- Examples 1 and 2 show that oral administration of GLA has an effect of suppressing the progression of AD-like pathology and high IgE production of NC / Nga mice.
- the in vitro class switch induction system using the mouse spleen cells was used to examine the effect of GLA on IgE production in vitro.
- spleen cells were collected from NC / Nga mice by the following method. Eight-week-old NC / Nga mice bred in an SPF environment without dermatitis-like findings or hyper IgEemia were killed by cervical prolapse and their spleens were removed under aseptic conditions. The excised spleen was placed in an RPMI-1640 medium (about 3 ml) in a petri dish, and the cells were loosely disintegrated with sterile forceps. The spleen membrane was removed by placing the cells in a 15 ml Falcon tube. The cells suspended in the medium were centrifuged at 1500 rpm for 5 minutes to collect only the cells.
- the collected cells are suspended in 10 ml of sterilized lysis buffer at 4 ° C to lyse the cells, and then washed twice with sterile Milli Q PBS at 4 ° C to collect splenocytes. did. A part of the obtained spleen cells was stained with trypan blue (Trypan Blue Stain 0.4%: manufactured by LIFE TECHNOLOGIES) and counted with a hemocytometer.
- the amount of IgE of the culture supernatant in the class switch induction system was measured by the following method.
- a concentration of 2xl0 5 cells / ml per 1 ⁇ l in a plate (96 ⁇ l micro test plate for cell culture, flat bottom, low evaporation type, polystyrene with lid: manufactured by FALCON) Cells were scattered.
- IL-4 100 U / ml
- LPS 10 usD
- the GLA was added at 0 hours (at the start of culture), 48 hours, 72 hours, and Was added to the medium at each concentration (0, 10, 20, 40, 60, 80, 120, 160 g / ml).
- the addition of GLA was performed by diluting to an appropriate amount with ethanol so that the final concentration of ethanol was 0.1%.
- the cell proliferation ability was measured by the following method. Based on the number of cells counted by the method described above, use a RPMI-1640 medium to seed the cells at 2 ⁇ 10 5 cells / ml, and IL-4 (100 U / ml) and PS (10 g / ml) Stimulant was added.
- GLA was added to the medium at each concentration (0, 10, 20, 40, 60, 80, 120, 160 ⁇ g / ml).
- the addition of GLA was performed by diluting each to an appropriate amount with ethanol so that the final concentration of ethanol was 0.1%.
- a class switch stimulant to which only IL-4 was added, a substance to which only LPS was added, and a substance to which no stimulant was added were set.
- the proliferation activity was measured for 60 to 72 hours from the start of the culture.
- the cells were centrifuged at 300 rpm for 10 minutes, the culture plate was opened as it was, and the medium was dried in an oven at 60 ° C. After drying for about 6 hours, add fixative (70% ethanol, 0.5 M hydrochloric acid) cooled to -20 ° C and add 200/1 per well, and fix cells at -20 ° C for 30 minutes. Was. Excess BrdU and the fixing solution were completely removed by washing three times with PBS, 100% of nuclease solution was added, and the reaction was carried out at 37 ° C for 30 minutes.
- Fig. 5 shows the results of measuring the amount of IgE in the culture supernatant when GLA was added to the tuber induction system.
- GLA has the ability to suppress IgE production in vitro, and when applied to the early stage of IgE production, including class switch, suppresses IgE production in a dose-dependent manner. Results were obtained.
- the decrease in the amount of IgE production is caused by the fact that GLA controls the class switch itself in some way, or that GLA controls cell growth, and Since it was considered that this was caused by the decrease in the number of producing cells, the proliferation ability of the cells when GLA was added was measured.
- Fig. 6 shows the results.
- GLA may not suppress IgE production by suppressing cell growth but may suppress IgE production by another pathway.
- This experiment demonstrated that GLA also exhibited a ⁇ g E production inhibitory effect in vitro. It became white.
- no inhibitory effect was observed when GLA was added 72 hours after the initiation of cytokine stimulation that induces IgE production.Therefore, GLA produced IgE including class switch recombination of antibody genes. It is presumed that this is hindering the initial stage.
- the in vivo results showed that IgA production in AD / NCa mice with hyper IgEemia was not suppressed by oral administration of GLA for 2 months. It also seems to be consistent.
- IgE production inhibitor of the present invention is excellent in suppressing IgE production, it is effective for diseases caused by IgE production.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01955567A EP1319402A4 (en) | 2000-08-04 | 2001-08-03 | IgE FORMATION INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000237679A JP2002047176A (ja) | 2000-08-04 | 2000-08-04 | IgE産生抑制剤 |
JP2000-237679 | 2000-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002011718A1 true WO2002011718A1 (fr) | 2002-02-14 |
Family
ID=18729499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006704 WO2002011718A1 (fr) | 2000-08-04 | 2001-08-03 | Inhibiteurs de production d'ige |
Country Status (4)
Country | Link |
---|---|
US (1) | US20030166723A1 (ja) |
EP (1) | EP1319402A4 (ja) |
JP (1) | JP2002047176A (ja) |
WO (1) | WO2002011718A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
EP1660071A1 (en) * | 2003-08-18 | 2006-05-31 | Btg International Limited | Treatment of neurodegenerative conditions |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
JP2006306813A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 肥満細胞増殖抑制剤 |
WO2006085687A1 (ja) * | 2005-02-14 | 2006-08-17 | Suntory Limited | ジホモ−γ−リノレン酸(DGLA)を有効成分として含んで成る組成物 |
JP5546087B2 (ja) * | 2005-02-14 | 2014-07-09 | サントリーホールディングス株式会社 | 皮膚疾患経口治療または予防剤 |
JP2006306812A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
CN100374152C (zh) | 2005-12-23 | 2008-03-12 | 中国农业大学 | 一种过敏性反应抑制剂 |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
JP2009263384A (ja) * | 2009-07-01 | 2009-11-12 | Sonoko:Kk | I型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 |
US9220702B2 (en) | 2011-05-12 | 2015-12-29 | Nippon Suisan Kaisha, Ltd. | Composition for external use on skin for inflammatory diseases |
JP2012082226A (ja) * | 2012-01-25 | 2012-04-26 | Suntory Holdings Ltd | 皮膚疾患経口治療または予防剤 |
HUE055277T2 (hu) | 2013-12-04 | 2021-11-29 | Nippon Suisan Kaisha Ltd | Dihomo-gamma-linolénsavat tartalmazó mikrobális olaj és dihomo-gamma-linolénsavat tartalmazó mikrobális biomassza |
KR102391827B1 (ko) | 2014-06-04 | 2022-04-27 | 디에스 바이오파마 리미티드 | Dgla를 포함하는 약제학적 조성물 및 그의 용도 |
JP6214474B2 (ja) * | 2014-06-10 | 2017-10-18 | サントリーホールディングス株式会社 | 皮膚疾患経口治療または予防剤 |
JP2015145381A (ja) * | 2015-03-09 | 2015-08-13 | チャイナ アグリカルチュラル ユニバーシティ | アレルギー抑制剤の組成物及びキットならびにその使用方法 |
JP2020090448A (ja) * | 2018-12-04 | 2020-06-11 | 学校法人順天堂 | アレルギー性結膜炎予防又は治療剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014824A1 (en) * | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
JPH10191935A (ja) * | 1997-01-17 | 1998-07-28 | Nippon Ham Kk | 食肉製品及びその製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9125602D0 (en) * | 1991-12-02 | 1992-01-29 | Efamol Holdings | Method of preventing reocclusion of arteries |
US5441955A (en) * | 1993-11-19 | 1995-08-15 | Pathogenesis Corporation | Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof |
CN1125651C (zh) * | 1998-04-16 | 2003-10-29 | 欧维塔有限公司 | 新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物 |
-
2000
- 2000-08-04 JP JP2000237679A patent/JP2002047176A/ja active Pending
-
2001
- 2001-08-03 US US10/343,896 patent/US20030166723A1/en not_active Abandoned
- 2001-08-03 EP EP01955567A patent/EP1319402A4/en not_active Withdrawn
- 2001-08-03 WO PCT/JP2001/006704 patent/WO2002011718A1/ja not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014824A1 (en) * | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
JPH10191935A (ja) * | 1997-01-17 | 1998-07-28 | Nippon Ham Kk | 食肉製品及びその製造方法 |
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 130:347056 * |
HENZ B.M. ET AL.: "Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema", BR. J. DERMATOL., vol. 140, no. 4, 1999, pages 685 - 688, XP002948372 * |
See also references of EP1319402A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002047176A (ja) | 2002-02-12 |
EP1319402A4 (en) | 2006-05-03 |
EP1319402A1 (en) | 2003-06-18 |
US20030166723A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002011718A1 (fr) | Inhibiteurs de production d'ige | |
JP6871304B2 (ja) | ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法 | |
JP2003535138A (ja) | 治療効果のある物質−ii | |
RU2423139C2 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ Actinidia, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
CN104379155B (zh) | 包含裙带菜孢子叶和海鞘皮的混合物提取液的异位性皮肤炎改善用组合物 | |
KR101057007B1 (ko) | 꽈배기모자반(Sargassum siliquastrum) 추출물을 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물 | |
CN111407773A (zh) | 一种天然生物抗炎抗菌剂 | |
KR102456356B1 (ko) | 락토바실러스 혼합균주를 유효성분으로 포함하는, 월경전 증후군 완화용 조성물 | |
AU659085B2 (en) | Method of treatment with HSP70 | |
JPWO2006030907A1 (ja) | 網膜保護剤 | |
JP2016164138A (ja) | 筋分化促進組成物 | |
SG183565A1 (en) | Compositions comprising myristic acid and uses thereof | |
KR102114510B1 (ko) | 코엔자임 큐텐과 오메가 3의 복합제를 이용한 면역조절용 조성물 | |
KR20200053370A (ko) | 플로로탄닌을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물 | |
EP3210602B1 (en) | Composition for preventing or treating neurodegenerative diseases, containing ramalin | |
FR3007655A1 (fr) | Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques | |
US20240066017A1 (en) | Prevention or treatment of brain disease and adverse effects of cholinesterase inhibitors | |
KR102655961B1 (ko) | 4-헥실레조르시놀을 유효성분으로 포함하는 항노화용 조성물 | |
CN111728961B (zh) | 一种用于治疗老年痴呆的药物组合物及其用途 | |
KR102047074B1 (ko) | 네오리쿠로사이드를 유효성분으로 하는 항알레르기 조성물 | |
CN106420689A (zh) | 咖啡酸肉桂酯在制备预防或治疗脑缺血性损伤的药物、保健品或食品中的应用 | |
JP2022099530A (ja) | 短期記憶能力向上用組成物 | |
KR20220168960A (ko) | 감초 신품종 원감 또는 신원감을 포함하는 알레르기에 치료 및 예방에 효과있는 약제학적 조성물 및 그 치료제 | |
KR101481040B1 (ko) | [10]-진저다이온 또는 1-데하이드로-[10]-진저다이온을 포함하는 항 염증용 조성물 | |
KR20230033211A (ko) | 고깔양배추 추출물을 유효성분으로 함유하는 항염증 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10343896 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001955567 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001955567 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001955567 Country of ref document: EP |